Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion Can SNK01 administration improve cognitive assessment scores and biomarkers
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Moderate Alzheimer Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NKGen Biotech, Inc.
- Last updated on ClinicalTrials.gov
- October 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Behavioral Research Specialists, LLC · Glendale, CA
- Syrentis Clinical Research · Santa Ana, CA
Florida · 2
- K2 Medical Research · Maitland, FL
- AdventHealth Research Institute · Orlando, FL
New Jersey · 1
- Rutgers Health · Newark, NJ
New York · 1
- Alzheimer's Disease Research Center · Albany, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.